The weedkiller Roundup for sale in Encinitas, California, in 2017.Photograph: Mike Blake/Reuters · Photograph: Mike Blake/Reuters A group of 14 law firms representing nearly 20,000 plaintiffs is seeking to intervene in Bayer’s proposed class-action settlement of Roundup litigation, citing concerns that the deal will not be fair to cancer sufferers. The group filed both a motion to intervene and a motion for an extension of time for court preliminary approval of the deal in St Louis city circuit court in M ...

Bayer AG (OTC:BAYRY) on Tuesday proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer. The product was originally made by Monsanto, which Bayer acquired in 2018 for more than $60 billion. “Litigation uncertainty has plagued the company for years, and this settlement gives the company a road to closure,” said Bayer CEO Bill Anderson. If approved by the court, the settlement would reduce potential exposure stemming from a future Supreme C ...

Core Points - President Trump issued an executive order to promote domestic production of phosphorus and glyphosate, citing their importance for national defense and food security [2][5] - The order mandates Agriculture Secretary Brooke Rollins to implement regulations to increase the supply of these chemicals [4] - There is currently only one domestic producer of elemental phosphorus and glyphosate-based herbicides, making the supply chain vulnerable to foreign threats [5] Company Insights - Bayer, the manufacturer of glyphosate-based herbicide Roundup, is involved in ongoing litigation regarding the chemical's alleged links to cancer, with a proposed settlement of $7.25 billion for lawsuits [3] - Monsanto, now owned by Bayer, emphasized the necessity for U.S. farmers to access domestically produced crop protection tools like glyphosate and stated compliance with the executive order [7] - The executive order reflects a shift in the stance of health officials, who previously expressed concerns about glyphosate but now recognize its importance for farmers [6]

Group 1 - Bayer's Monsanto unit has proposed a U.S. class settlement of up to $7.25 billion to resolve claims that Roundup weedkiller caused Non-Hodgkins lymphoma [1][2] - The proposed settlement aims to cover the majority of pending cases in U.S. state and federal courts and will require judicial approval [2] - Bayer is preparing additional settlements for existing U.S. Roundup cases valued at approximately $3 billion [2] Group 2 - The settlement proposal includes a provision for individuals diagnosed with Non-Hodgkins lymphoma who were exposed to Roundup to file claims for up to 21 years [3] - Bayer expects its provisions and litigation liabilities to increase from €7.8 billion to €11.8 billion, with anticipated litigation-related payouts of around €5 billion in 2026 [3] - The company has postponed the publication of its 2025 results and 2026 guidance to March 4 to reflect these agreements [4]

Bayer (OTCPK:BAYR.Y) Update Summary Company Overview - Bayer is involved in the glyphosate litigation, specifically related to its subsidiary, Monsanto, and has reached a class settlement agreement in the United States [1][3]. Key Points Settlement Agreement - Bayer announced a class settlement agreement to resolve current and potential future glyphosate litigation in the U.S. [3][4]. - The settlement involves capped annual payments declining over time, spread over a period of up to 21 years, pending court approval [3][4]. - The settlement aims to provide speed and containment over prolonged legal battles, allowing Bayer to focus on its core mission [3][4]. Financial Implications - Bayer increased its litigation provision from EUR 7.8 billion to EUR 11.8 billion, with approximately EUR 9.6 billion allocated for glyphosate-related claims [10][36]. - The company expects litigation-related cash outflows to total around EUR 5 billion in 2026, leading to negative free cash flow for that year [11][12]. - Annual payments for litigation-related costs are anticipated to be around EUR 1 billion for the next five years, decreasing significantly thereafter [11][12]. Supreme Court Case - The Supreme Court is set to review Bayer's case, which could provide clarity on federal preemption regarding glyphosate claims [5][17]. - A favorable ruling could address cases not covered by the settlement and disincentivize opt-outs from the settlement [5][17][64]. Regulatory Clarity - Bayer emphasizes the need for regulatory clarity on crop protection products, which is critical for U.S. farmers and the agricultural industry [6][13]. - The company is preparing to launch a new herbicide, Icafolin, and seeks to ensure that American farmers have access to essential agricultural products [6][13]. Class Settlement Details - The settlement covers current and potential future plaintiffs exposed to Roundup before February 17, 2026, with a long-term claims program lasting up to 21 years [19][20]. - The settlement is supported by leading plaintiff law firms, indicating a fair arrangement for plaintiffs [19][20]. - A robust notice process will inform class members about their rights regarding the settlement [20][21]. Future Strategy - Bayer aims to refocus on its mission of "Health for All, Hunger for None" and is committed to advancing its pharmaceuticals and agricultural products [24][23]. - The company is undergoing a transformation to enhance operational efficiency and strategic flexibility [56][57]. Additional Considerations - The settlement is expected to impact employee jobs and divert funding from new product development towards litigation costs [14]. - Bayer maintains objections to the current tort system, which necessitates such settlements [14]. Conclusion - Bayer's recent settlement agreement represents a significant step towards resolving ongoing litigation and refocusing on its core business objectives. The financial implications and the upcoming Supreme Court ruling will be critical in shaping the company's future strategy and operational focus.

Core Viewpoint - The U.S. Supreme Court will review the Durnell Roundup™ case, which is significant for Monsanto as it addresses the split in authority among federal circuit courts regarding federal preemption in Roundup™ litigation [1] Summary by Relevant Categories Legal Developments - Monsanto petitioned the Supreme Court to hear the Durnell case in April 2025, with an expected decision on the merits during the Court's 2026 session, which concludes in June [1] Industry Impact - The Supreme Court's decision to take the case is viewed positively for U.S. farmers, indicating potential implications for the agricultural sector and the use of Roundup™ products [1]

Core Viewpoint - Bayer's Monsanto has initiated a lawsuit against COVID-19 vaccine manufacturers Pfizer, BioNTech, and Moderna, claiming they have improperly utilized its messenger RNA technology in the production of their vaccines [1] Group 1: Legal Action - The lawsuit was filed in Delaware federal court, indicating a formal legal challenge to the vaccine makers [1] - The core allegation revolves around the alleged misuse of messenger RNA technology, which is critical in the development of mRNA vaccines [1] Group 2: Implications for the Industry - This legal action could have significant implications for the biotechnology and pharmaceutical sectors, particularly regarding intellectual property rights and technology usage in vaccine development [1] - The outcome of this lawsuit may influence future collaborations and innovations within the mRNA technology space [1]

RT Peter St Onge, Ph.D. (@profstonge)RFK: Monsanto created Celiac DiseaseBtw, here's a chart of glyphosate on wheat (i.e. Roundup) and celiac disease hospital discharges: https://t.co/cY5fqRTh0m ...

I'm starting with Warner Brothers. This guy. Okay, w bd their shares have been up nearly 2%, so it's feeling the second round of bids right from Netflix.Paramount Skydance's Comcast that includes a mostly cash offer from Netflix. Paramount's offer reportedly includes debt financing from Apollo. Sources are saying Middle East funds also contributing to that.But you had bankers from Paramount, you know Netflix, they were all busy over Thanksgiving. You know, the long weekend sources saying an auction could wr ...

Core Viewpoint - The U.S. Solicitor General supports Bayer's request for the Supreme Court to review rulings regarding the health impacts of Roundup, potentially affecting the company's liability in ongoing lawsuits [1][7]. Bayer's Stock Performance - Shares of Bayer surged 12% on the German exchange following the Solicitor General's support for the Supreme Court review [1]. Regulatory Background - The Environmental Protection Agency has stated that glyphosate, a key ingredient in Roundup, is "not likely to be carcinogenic in humans," and the Food and Drug Administration has approved numerous labels for Roundup without cancer warnings [2][7]. Legal Arguments - Bayer contends that since federal agencies deem glyphosate safe, customers should not be able to sue under state laws for failing to warn about cancer risks. Most of the ongoing lawsuits are based on "failure-to-warn theories," which could be invalidated by a favorable Supreme Court ruling for Bayer [3][4]. Implications for Investors - A Supreme Court ruling in favor of Bayer could prevent the company from paying billions in settlements related to cancer risk allegations, while a ruling against it could benefit thousands of cancer patients and their families [4]. Bayer's Strategy - Bayer welcomes the Solicitor General's support, stating that a Supreme Court ruling would clarify the company's obligations under state laws versus federal determinations of chemical safety. The company aims to significantly reduce litigation by the end of 2026 [5]. Acquisition Context - Bayer acquired Monsanto in 2018 for $63 billion, and shortly after the acquisition, a California jury found Monsanto liable for failing to warn about Roundup's potential cancer risks [5].